Most Active Stocks in NASDAQ 100 Pre-Market: BBAI, HBI, TSLL, WT, ACHR, INTC, WOW, WMT, SQQQ, HOOD, NVDA, ETHA

The NASDAQ 100 Pre-Market Indicator is up 158.98 to 23,685.61, with total Pre-Market volume at 109,286,356 shares traded. The most active stocks include BigBear.ai, Hanesbrands, Direxion Daily TSLA Bull 2X Shares, WisdomTree, Archer Aviation, Intel, WideOpenWest, Walmart, ProShares UltraPro Short QQQ, Robinhood Markets, NVIDIA, and iShares Ethereum Trust. The views and opinions expressed are those of the author and not necessarily those of Nasdaq, Inc.

IDEXX Laboratories (IDXX) has emerged as a standout performer on the Nasdaq-100, securing the second-best-performing stock position behind Palantir (PLTR). According to a recent report, IDEXX's shares have surged by 59.4% year-to-date, outpacing major tech giants like Nvidia (NVDA), Microsoft (MSFT), and Meta (META) [1].

Founded in 1983, IDEXX Laboratories specializes in diagnostic and software solutions for veterinary and water testing markets. The company's market cap has grown significantly from around $34 billion at the start of the year to $54.9 billion. This impressive growth is largely attributed to its consistent earnings beats over the past four quarters and robust quarterly results.

In Q2 2025, IDEXX reported revenues of $1.1 billion, reflecting an 11% increase year-over-year. The Companion Animal Group, the company's largest segment, achieved 10% organic revenue growth, with the IDEXX VetLab consumables segment seeing a 14% surge. Earnings per share soared by 49% to $3.63, surpassing the consensus estimate of $3.30. Gross and operating margins also improved to 62.6% and 33.6%, respectively.

Despite a decrease in net cash from operating activities for the first half of 2025, IDEXX ended Q2 with a cash balance of $164.6 million, comfortably above its short-term debt of $75 million. Encouraged by its performance, IDEXX raised its revenue guidance for the year to between $4.21 billion and $4.28 billion, with an increased EPS range of $12.40-$12.76.

IDEXX's strategic focus on high-margin consumable products and recurring revenues has ensured financial stability and growth. The company's diagnostic infrastructure, including the widely used Catalyst One analyzer and the innovative inVue Dx cellular analyzer, has cemented its leadership in the veterinary diagnostics space. The recent launch of the Cancer Dx panel, capable of detecting canine lymphoma, has seen strong adoption, indicating promising future growth.

While IDEXX's stock is trading at a premium with forward price-earnings, price-sales, and price-cash flow ratios significantly higher than industry averages, analysts have rated it a "Moderate Buy." With a mean target price of $558.30, the stock's rally continues to attract investor interest.

References:
[1] https://www.indexbox.io/blog/idexx-laboratories-a-top-performer-on-nasdaq-100/